High-rolling investors have positioned themselves bearish on Kenvue KVUE, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in KVUE often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 10 options trades for Kenvue. This is not a typical pattern.
The sentiment among these major traders is split, with 30% bullish and 70% bearish. Among all the options we identified, there was one put, amounting to $30,251, and 9 calls, totaling $717,315.
Expected Price Movements
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $22.5 for Kenvue over the last 3 months.
Volume & Open Interest Development
In terms of liquidity and interest, the mean open interest for Kenvue options trades today is 45988.6 with a total volume of 14,795.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Kenvue's big money trades within a strike price range of $20.0 to $22.5 over the last 30 days.
Kenvue Call and Put Volume: 30-Day Overview
Largest Options Trades Observed:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| KVUE | CALL | SWEEP | BULLISH | 02/16/24 | $20.00 | $365.7K | 35.6K | 6.1K |
| KVUE | CALL | TRADE | BEARISH | 02/16/24 | $20.00 | $59.2K | 35.6K | 4.1K |
| KVUE | CALL | TRADE | NEUTRAL | 12/15/23 | $21.00 | $57.0K | 10.3K | 2 |
| KVUE | CALL | TRADE | BEARISH | 12/01/23 | $20.00 | $54.9K | 56.5K | 26 |
| KVUE | CALL | SWEEP | BEARISH | 02/16/24 | $20.00 | $52.4K | 35.6K | 1.5K |
About Kenvue
Kenvue is the world's largest pure-play consumer health company by sales, generating $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio includes a wide array of some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and ever-changing consumer preferences, many of Kenvue's brands are the global leader in their respective segment thanks to their strong brand power.
After a thorough review of the options trading surrounding Kenvue, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Kenvue's Current Market Status
- With a trading volume of 4,912,581, the price of KVUE is up by 1.42%, reaching $19.68.
- Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
- Next earnings report is scheduled for 85 days from now.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Kenvue with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
